The poster highlights case studies of the first three participants to complete the 6-month Phase 2 trial, all of whom entered the study on G-CSF therapy. Overall: Mavorixafor was generally well tolerated when used in combination with G-CSF, with no serious adverse events reported; While 4 infections were reported during the first two months of the trial, no infections were reported during the following 4 months of the trial, despite reductions in G-CSF dosing in two of the three participants; The data continue to support the potential of mavorixafor to raise absolute neutrophil counts (ANC) and enable reduction in G-CSF dosing in patients with chronic neutropenia; The data informed the design of the planned pivotal, global Phase 3 clinical trial of mavorixafor in certain chronic neutropenic disorders, as well as the selection of ANC and infection as primary endpoints; the trial is expected to initiate in the first half of 2024.
The poster also highlighted results from a recent qualitative
'Given that there has been little innovation in the classical hematology space and no innovation for patients with chronic neutropenia for the past 30 years, we are very pleased with the data continuing to emerge from our ongoing CN Phase 2 clinical trial,' said
About
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by the words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target,' or other similar terms or expressions that concern X4's expectations, strategy, plans, or intentions. Forward-looking statements include, without limitation, statements regarding the clinical development and therapeutic potential of mavorixafor for the treatment of chronic neutropenic disorders; expectations regarding timing for reporting data from ongoing clinical studies or the initiation of future clinical trials, including the timing of reporting additional data from X4's ongoing Phase 2 trial of mavorixafor in certain chronic neutropenic disorders and the timing of commencing a Phase 3 trial. Any forward-looking statements in this press release are based on management's current expectations and beliefs. Actual events or results may differ materially from those expressed or implied by any forward-looking statements contained herein, including, without limitation, uncertainties inherent in the initiation and completion of clinical trials and clinical development; the risk that trials and studies may not have satisfactory outcomes; the risk that the outcomes of earlier clinical trials will not be predictive of later clinical trial results; the risk that initial or interim results from a clinical trial may not be predictive of the final results of the trial or the results of future trials; the risks related to X4's ability to raise additional capital and other risks and uncertainties, including those described in the section entitled 'Risk Factors' in X4's Quarterly Report on Form 10-Q filed with the
Contact:
Email: daniel@lifesciadvisors.com
Tel: (617) 430-7576
(C) 2023 Electronic News Publishing, source